News

Trial Update The full amendment pack for Substantial Amendment 05 is now available. Please access the password protected area of this website. The Substantial Amendment 05 Document Pack file is located under the Essential Documents page. The team have also put together a short slide set outlining the changes which should help to reduce workload at sites. This is titled Substa ...

The full amendment pack for Substantial Amendment 03 and Non-Substantial Amendment 04 is now available. Please access the password protected Essential Documents page of this website. The Substantial Amendment 03 and Non-Substantial Amendment 04 Document Pack file is located under the Regulatory/Approval Documents section of the page, under the Substantial Amendment Packs headin ...

The ESMO Congress serves as a globally influential platform in oncology, bringing together clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from around the world. The STAMPEDE2 trial will be presented at the event, with each of its three comparisons detailed in a set of posters. Please find links to these posters below: ESMO STA ...

We are thrilled to share that the STAMPEDE2 trial has randomised its first patient into Comparison S at the Royal Marsden Hospital Chelsea, on Tuesday 9th July. Comparison S aims to explore the potential benefits of adding Stereotactic Ablative Body Radiotherapy (SABR) to standard of care for men whose prostate cancer has spread to a limited number of body areas. A big thank ...

We are delighted to announce that the STAMPEDE2 trial recruited its first patient at the Royal Marsden Hospital Sutton on Friday 21st June. The patient was recruited into Comparison P which is testing the addition of PSMA-Lutetium to standard care. We are full steam ahead trying to activate as many sites as possible across the UK and aim to recruit up to 5000 patients over th ...